Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HH-009 in FGF19-positive advanced or unresectable hepatocellular carcinoma after systemic therapy failure
ChiCTR2600121172Phase 2Not yet recruiting
- Sponsor
- Nanjing Tianyinshan Hospital
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of HH-009 in hepatocellular carcinoma (HCC) (2 arms), sponsored by Nanjing Tianyinshan Hospital. Primary endpoint: Progression-free survival. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
HH-009
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2600121172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121172.